Acquired pure red cell aplasia (PRCA) can be associated with lymphoproliferative disease of granular T lymphocytes (T-LDGL), also known as T-cell large granular lymphocyte leukemia. Fifteen adult patients with PRCA associated with T-LDGL comprise this study. Neutropenia and rheumatoid arthritis were uncommon. All patients responded to immunosuppressive therapy. The 2 most commonly used treatments were prednisone and cyclophosphamide ± corticosteroids, producing overall response rates of 50% and 60%, respectively. Treatment with cyclophosphamide was associated with a more durable remission (median, 60 versus 7.5 months). After a median follow-up of 67 months, 2 patients died of treatment-related complications, one from myelodysplasia and another from cyclosporine-induced renal failure. The clinical course and treatment responses of PRCA associated with T-LDGL in this series were similar to the general group of PRCA. Because T-LDGL is frequently underdiagnosed, it is likely that a significant proportion of idiopathic or primary PRCA is in fact secondary to T-LDGL.

Common to the pathophysiology of bone marrow failure syndromes, including aplastic anemia, pure red cell aplasia (PRCA), and a subset of myelodysplastic diseases, is an immune-mediated suppression of marrow progenitor cells by cytotoxic T lymphocytes.1-5 Lymphoproliferative disease of granular T lymphocytes (T-LDGL) is a clonal disorder of cytotoxic T lymphocytes that usually manifests as neutropenic infections and is associated with autoimmune disorders, most commonly rheumatoid arthritis. T-LDGL can present as failure of hematopoiesis or immune-mediated destruction in any one or a combination of the several myeloid cell lines, including red cells, neutrophils, and platelets. The frequent associations of these bone marrow failure syndromes with T-LDGL and recent findings on pathogenic mechanisms of T-LDGL suggest that T-LDGL may share a similar pathology to these other syndromes.6,7 We have previously reported that T-LDGL is a disorder frequently associated with PRCA.8 In our institutional series of 203 patients with T-LDGL, 15 (7%) patients presented as PRCA.6 This report reviews our clinical experience in 15 patients with PRCA in the setting of T-LDGL. This series included an update on 9 patients previously reported.8 

After receiving the approval of the institutional review board of the Mayo Foundation, our database of patients with T-LDGL was reviewed for associated PRCA. A diagnosis of PRCA was made on the basis of clinical and bone marrow findings. Anemia with reticulocyte count of less than 1% had to be present. On bone marrow examination, there was almost complete absence of erythropoietic precursors or maturation arrest at the pronormoblastic stage. Maturation of other hematopoietic cell lines was normal. Other known causes of PRCA were excluded. Published criteria for T-LDGL was used.9 Complete response (CR) was defined as normalization of hemoglobin. Partial response (PR) was defined as an increase in hemoglobin level by 2 g/dL or more or by a 50% reduction in transfusion requirements. Any response less than partial was considered no response (NR). The percentage and absolute counts of granular lymphocytes in the peripheral blood were calculated as previously reported.7 Multiparametric flow cytometry of the peripheral blood or bone marrow and immunohistochemical staining of bone marrow biopsy was used to study lymphocytic immunophenotype. T-cell receptor gene rearrangement study was performed by using either the Southern blot analysis or polymerase chain reaction.

We found 15 patients having PRCA associated with T-LDGL. In all cases, the diagnosis of PRCA was made concurrently with T-LDGL. Of those 15 patients, 8 were women. The median age at diagnosis was 66 years (range, 28-88 years). Associated medical conditions included B-cell non-Hodgkin lymphoma (2), B-cell chronic lymphocytic leukemia (1), thymoma (1), porphyria cutanea tarda (1), rheumatoid arthritis (1), inflammatory bowel disease (1), and polyendocrine failure (1). In the patient with a history of thymoma, thymectomy was performed 6 years before the diagnosis of T-LDGL and PRCA. All patients presented with symptoms because of anemia and were transfusion dependent. Except for pallor, there were no other physical findings. Laboratory findings are shown in Table 1. Absolute lymphocytosis in the peripheral blood was noted in only 6 patients. In the rest of the patients without absolute lymphocytosis, increase in granular lymphocytes could be identified by examination of the peripheral blood or the bone marrow.

Table 1.

Laboratory findings of 15 patients with pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes

Median (range)Normal values
Hemoglobin (g/dL) 7.8  (5.0-10.5) 12.0-17.5  
Mean corpuscular volume (fL) 90  (83.0-117.9) 81.2-98.3  
White cell count (× 109/L) 6.6  (3.4-37.0) 3.5-10.5  
Absolute neutrophil count (× 109/L) 3.09  (0.12-5.41) 1.70-7.0  
Absolute lymphocyte count (× 109/L) 2.31  (1.06-29.97) 0.90-2.90 
Absolute granular lymphocyte count
(× 109/L) 
0.45  (0.30-7.21) 0.10-0.50  
Granular lymphocyte (%) 31  (10-59) 5-25 
Median (range)Normal values
Hemoglobin (g/dL) 7.8  (5.0-10.5) 12.0-17.5  
Mean corpuscular volume (fL) 90  (83.0-117.9) 81.2-98.3  
White cell count (× 109/L) 6.6  (3.4-37.0) 3.5-10.5  
Absolute neutrophil count (× 109/L) 3.09  (0.12-5.41) 1.70-7.0  
Absolute lymphocyte count (× 109/L) 2.31  (1.06-29.97) 0.90-2.90 
Absolute granular lymphocyte count
(× 109/L) 
0.45  (0.30-7.21) 0.10-0.50  
Granular lymphocyte (%) 31  (10-59) 5-25 

Clonal T-cell receptor gene rearrangement, 15 of 15 patients; positive direct antiglobulin test, 1 of 10 patients; positive antinuclear antibody test, 4 of 6 patients; rheumatoid factor, 1 of 4 patients; antineutrophil antibody, 0 of 2 patients. Cytogenetic studies, (n = 10 patients). Normal (8); loss of Y chromosome (1); complex abnormality (1). Peripheral blood flow cytometry, (n = 12 patients). CD3+/CD8+ (8); normal (4). Immunophenotypes studied include CD2, CD3, CD5, CD7, CD3/CD8, and CD3/CD4.

Bone marrow immunohistochemistry, (n = 9 patients). Increase in CD3+ and CD8+ cells (9); increase in CD57+ cells (8).

Seven patients were initially treated with prednisone (3 CR, 4 NR), and 5 patients received a combination of cyclophosphamide and corticosteroids (4 CR, 1 NR). Other initial treatments included chlorambucil/prednisone (1/1 NR), methotrexate (1/1 NR), and cyclophosphamide/doxorubicin/vincristine/prednisone (1/1 CR). The treatment outcome from initial therapy until a response was obtained is outlined in Figure 1. In patients who initially responded to cyclophosphamide (5), the remission duration ranged from 22 to 120 months. All responded again to cyclophosphamide. In contrast, all prednisone responders (3) relapsed within 5 to 10 months of treatment. They were retreated with either oral cyclophosphamide (1 CR, 1 NR) or prednisone (1 CR). Salvage treatments used included cyclosporine, methotrexate, fluoxymesterone, antithymocyte globulin, or combination chemotherapy. The usual dosages of immunosuppressive agents used were prednisone, 1 mg/kg/d; cyclophosphamide, 50-100 mg/d; cyclosporine, 10 mg/kg/d; and methotrexate, 7.5-15 mg/wk. In general, a specific treatment was tried for at least 2 to 3 months unless side effects were not tolerated. The use of cytotoxic agents was limited to a total of 6 to 12 months after a response was achieved, whereas noncytotoxic immunosuppressive agents were given as long as necessary to control the disease. After a median follow-up of 67 months (range, 22-113 months), 13 patients were alive; 10 patients had PR, and 3 patients were in unmaintained CR. Continued therapy was necessary in all of the patients in PR. The clinical course was characterized by frequent relapses, although durable responses could be achieved. Two patients died of treatment-related complications, one from acute myeloid leukemia arising from myelodysplasia after cyclophosphamide treatment and another from cyclosporine-induced renal failure.

Fig. 1.

Treatment outcomes of patients with PRCA associated with T-LDGL from diagnosis until first response.

CR indicates complete response; PR, partial response; NR, no response; DNT, did not tolerate; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CVP, cyclophosphamide/vincristine/prednisone; pt, patient.

Fig. 1.

Treatment outcomes of patients with PRCA associated with T-LDGL from diagnosis until first response.

CR indicates complete response; PR, partial response; NR, no response; DNT, did not tolerate; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CVP, cyclophosphamide/vincristine/prednisone; pt, patient.

Close modal

It is now evident that a close association exists between T-LDGL and PRCA.8,11,12 In our experience, PRCA is the second most common hematologic disease found in T-LDGL patients, exceeded only by autoimmune hemolytic anemia.2 In this subset of T-LDGL with concomitant PRCA, it is notable that rheumatoid arthritis and neutropenia were infrequently associated (1 and 2 patients, respectively). A careful examination of the peripheral blood is always necessary as lymphocytosis was observed in less than half of our cases. Similarly, bone marrow involvement by granular lymphocytes was mostly subtle. Peripheral blood flow cytometry detected an abnormal T-cell population in only 8 of the 12 patients studied. This finding was probably because of the limited antibody panel we used (Table1) for routine T-cell analysis. A more detailed analysis of the CD8+ subset, including determinations of CD16, CD56, and CD57, might have provided us more information. Initial case reports and series of T-LDGL included only cases that were obvious on clinical grounds, ie, those with evident lymphocytosis and symptoms, features consistent with a later diagnosis.13,14 As is true when there is a better awareness of a newly described disease, T-LDGL earlier in its natural history is being recognized in a more recent reported series.10 In fact, the diagnostic criteria for T-LDGL were modified to reflect this recognition.15 Nevertheless, we believe that T-LDGL remains a disease that is underdiagnosed.

The 2 most commonly used treatments in our series were prednisone alone and cyclophosphamide with or without concurrent low-dose corticosteroids. As initial therapy, cyclophosphamide ± corticosteroids produced a better overall response rate (CR + PR) than prednisone alone (80% versus 43%). When uses such as initial and salvage therapies were considered together, the overall response rates for cyclophosphamide ± corticosteroids and prednisone were similar (60% and 50%, respectively). Treatment with cyclophosphamide was, however, associated with a longer duration of response, 60 months (range, 22-117 months) versus 7.5 months (range, 5-43 months). Cyclosporine and methotrexate were used in the setting of treatment failure from other agents, with responses noted in 2 of 3 and 1 of 3 patients, respectively. These responses were durable, but, in each case, the treatment had to be maintained to achieve continued remission. All patients achieved remission after sequential immunosuppressive therapy. This finding suggests that T-LDGL association may be prognostic of a good response to immunosuppression. Considering that the clinical course and treatment responses of PRCA associated with T-LDGL are similar to the general group of PRCA and that T-LDGL is probably an underdiagnosed disorder, it is likely that a significant proportion of idiopathic or primary PRCA is, in fact, secondary to T-LDGL.

We thank Janice Hodnefield, Barbara Todd, and William Wittrock for their laboratory assistance.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Kagan
WA
Ascensao
JA
Pahwa
RN
et al
Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis.
Proc Natl Acad Sci U S A.
73
1976
2890
2894
2
Maciejewski
JP
Hibbs
JR
Anderson
S
Katevas
P
Young
NS
Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure.
Exp Hematol.
22
1994
1102
1110
3
Abkowitz
JL
Kadin
ME
Powell
JS
Adamson
JW
Pure red cell aplasia: lymphocyte inhibition of erythropoiesis.
Br J Hematol.
63
1986
59
67
4
Akard
LP
Brandt
J
Lu
L
Adamson
JW
Chronic T cell lymphoproliferative disorder and pure red cell aplasia.
Am J Med.
83
1987
1069
1074
5
Knox
SJ
Greenberg
BR
Anderson
RW
Rosenblatt
LS
Studies of T-lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations.
Blood.
61
1983
449
455
6
Go
RS
Tefferi
A
Li
CY
Lust
JA
Morice
WG
Phyliky
RL
Lymphoproliferative disease of granular T lymphocytes: a single institution experience with 203 cases [abstract].
Blood.
94
1999
515a
7
Lamy
T
Loughran
TP
Jr
Current concepts: large granular lymphocyte leukemia.
Blood Rev.
13
1999
230
240
8
Lacy
MQ
Kurtin
PJ
Tefferi
A
Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.
Blood.
87
1996
3000
3006
9
Go
RS
Tefferi
A
Li
CY
Lust
JA
Phyliky
RL
Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia.
Blood.
96
2000
3644
3646
10
Dhodapkar
MV
Li
CY
Lust
JA
Tefferi
A
Phyliky
RL
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
Blood.
84
1994
1620
1627
11
Mamiya
S
Itoh
T
Miura
AB
Acquired pure red cell aplasia in Japan.
Eur J Haematol.
59
1997
199
205
12
Kwong
YL
Wong
KF
Association of pure red cell aplasia with T large granular lymphocyte leukaemia.
J Clin Pathol.
51
1998
672
675
13
McKenna
RW
Parkin
J
Kersey
JH
Gajl-Peczalska
KJ
Peterson
L
Brunning
RD
Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics.
Am J Med.
62
1977
588
596
14
Pandolfi
F
Loughran
TP
Starkebaum
G
et al
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes: a multicenter study.
Cancer.
65
1990
341
348
15
Semenzato
G
Zambello
R
Starkebaum
G
Oshimi
K
Loughran
TP
The lymphoproliferative diseases of granular lymphocytes: updated criteria for diagnosis.
Blood.
89
1997
256
260

Author notes

Robert L. Phyliky, Mayo Clinic, Division of Hematology, 200 First St, SW, Rochester, MN 55905; e-mail:[email protected].

Sign in via your Institution